Opdivo-Yervoy Combo Shows Signs of Activity in CRPC Patients with Metastases

Opdivo-Yervoy Combo Shows Signs of Activity in CRPC Patients with Metastases
A combination of Bristol-Myers Squibb’s immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor burden in castration-resistant prostate cancer patients whose tumors have spread, interim Phase 2 results show. Findings from the CheckMate 650 trial (NCT02985957) were recently shared at the 2019 Genitourinary Cancers Symposium in San Francisco in a presentation titled, “Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).” “The results from CheckMate 650 provide strong rationale for the development of combination immune checkpoint therapy for the treatment of prostate cancer, which is considered a cold tumor with few tumor-infiltrating lymphocytes,” Padmanee Sharma, MD, PhD, professor of genitourinary medical oncology and immunology at The University of Texas MD Anderson Cancer Center, said in a press release. “The clinical results from this study are encouraging and provide the foundation to test the combination strategy in a larger cohort of patients,” she said. Generally, prostate cancer tumors have very little infiltration of immune cells in their environment, which has largely limited the use of immune checkpoint inhibitors as single agents. These treatments counteract signals from cancer cells to suppress an immune anti-tumor response, thereby promoting the body’s own defenses against cancer cells. However, immune cells must penetrate the tumors to exert their function. In some cancers, combinations of immune checkpoint inhibitors targeting different molecules have led to better responses than any of these treatments alone. This led Bristol-Myers Squibb to design a Phase 2 trial
Subscribe or to access all post and page content.